Ieq Capital LLC cut its holdings in United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 31.4% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,919 shares of the biotechnology company’s stock after selling 8,183 shares during the period. Ieq Capital LLC’s holdings in United Therapeutics were worth $9,710,000 as of its most recent SEC filing.
Other large investors have also recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in United Therapeutics during the 2nd quarter valued at about $2,868,735,000. Jupiter Topco LLC purchased a new stake in shares of United Therapeutics in the second quarter valued at about $450,140,000. Bank of New York Mellon Corp purchased a new stake in shares of United Therapeutics in the second quarter valued at about $159,522,000. Caisse de depot et placement du Quebec acquired a new stake in shares of United Therapeutics in the second quarter valued at approximately $154,304,000. Finally, Legal & General Group Plc acquired a new stake in shares of United Therapeutics in the second quarter valued at approximately $112,209,000. 94.08% of the stock is owned by institutional investors and hedge funds.
Trending Headlines about United Therapeutics
These are some of the UTHR headlines that stood out recently:
- Positive Sentiment: The first clinical UThymoKidney transplant advances United Therapeutics’ effort to develop an additional source of transplantable kidneys. Progress in the trial could support the long-term value of its xenotransplantation program, though clinical and regulatory risks remain. Article: First clinical xenotransplant in EXTEND study
- Neutral Sentiment: One article argues UTHR may be below fair value after the transplant announcement. That is an opinion-based valuation view, not a new financial forecast or clinical result. Article: UTHR may be below fair value
- Negative Sentiment: Recent insider-sale reports may weigh on sentiment: CEO Martine Rothblatt sold 5,410 shares for about $3.13 million, while EVP Paul Mahon sold 8,300 shares for about $4.69 million. Rothblatt retained 324,443 shares after her sale; the transactions alone do not establish a change in the company’s outlook. Article: CEO share sale
Wall Street Analyst Weigh In
A number of research analysts have recently weighed in on UTHR shares. BTIG Research raised their price objective on shares of United Therapeutics from $728.00 to $768.00 and gave the stock a “buy” rating in a research note on Wednesday, November 4th. HC Wainwright assumed coverage on United Therapeutics in a report on Monday, November 9th. They issued a “buy” rating and a $660.00 price target for the company. UBS Group set a $725.00 target price on United Therapeutics in a research report on Monday, October 19th. JPMorgan Chase & Co. decreased their price target on United Therapeutics from $710.00 to $695.00 and set an “overweight” rating on the stock in a research note on Wednesday, October 28th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $728.00 price target on shares of United Therapeutics in a report on Wednesday, October 14th. Twelve research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $676.40.
Read Our Latest Stock Report on United Therapeutics
United Therapeutics Trading Down 0.8%
Shares of United Therapeutics stock opened at $554.73 on Friday. The company has a fifty day moving average price of $550.00 and a 200 day moving average price of $538.90. United Therapeutics Corporation has a twelve month low of $455.63 and a twelve month high of $614.23. The stock has a market cap of $23.63 billion, a price-to-earnings ratio of 20.93, a price-to-earnings-growth ratio of 3.69 and a beta of 0.49.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last announced its earnings results on Wednesday, November 4th. The biotechnology company reported $5.71 EPS for the quarter, missing the consensus estimate of $6.01 by ($0.30). The company had revenue of $832.50 million for the quarter, compared to analysts’ expectations of $781.14 million. United Therapeutics had a net margin of 38.61% and a return on equity of 19.18%. The business’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $7.16 earnings per share. Analysts forecast that United Therapeutics Corporation will post 25.08 earnings per share for the current year.
United Therapeutics declared that its Board of Directors has initiated a stock repurchase plan on Thursday, October 22nd that permits the company to repurchase $2 billion in outstanding shares. This buyback authorization permits the biotechnology company to buy up to 8.3% of its shares through open market purchases. Share buyback plans are generally an indication that the company’s management believes its shares are undervalued.
Insider Transactions at United Therapeutics
In other news, EVP Paul Mahon sold 8,300 shares of the business’s stock in a transaction dated Thursday, November 19th. The shares were sold at an average price of $565.09, for a total value of $4,690,247.00. Following the completion of the sale, the executive vice president owned 45,172 shares of the company’s stock, valued at approximately $25,526,245.48. The trade was a 15.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Martine Rothblatt sold 5,410 shares of the company’s stock in a transaction that occurred on Wednesday, November 18th. The shares were sold at an average price of $578.83, for a total value of $3,131,470.30. Following the sale, the chief executive officer owned 324,443 shares in the company, valued at $187,797,341.69. The trade was a 1.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 408,148 shares of company stock valued at $220,922,751. 8.60% of the stock is currently owned by corporate insiders.
United Therapeutics Profile
United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.
See Also
- Five stocks we like better than United Therapeutics
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR – Free Report).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
